Ignite Creation Date:
2024-05-06 @ 9:18 AM
Last Modification Date:
2024-10-26 @ 12:13 PM
Study NCT ID:
NCT02958410
Status:
UNKNOWN
Last Update Posted:
2019-06-25
First Post:
2016-11-06
Brief Title:
A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
Sponsor:
Southwest Hospital China
Organization:
Southwest Hospital China
Study Overview
Official Title:
A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
Status:
UNKNOWN
Status Verified Date:
2019-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor TCAR-T cells in the treatment of lymphocyte derived malignancies
Detailed Description:
CD30 is originally described as a marker of Hodgkins and Reed-Sternberg cells in Hodgkins lymphoma CD30 antibody has been applied to treat lymphocyte derived malignancies To explore the potency of CD30 in CAR-T therapy this trial is designed and conducted to test the safety and effect of CD30-targeted CAR-T
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None